| Title | Apoptosis and the pathogenesis of Hashimoto’s thyroiditis | |
| Authors | George Mastorakos¹, Ioannis Ilias¹ and Nicholas Mitsiades²
1. Endocrine Unit, Evgenidion Hospital, University of Athens, Greece 2. Developmental Endocrinology Branch, National Institutes of Health, Bethesda, Maryland, USA |
|
| Citation | Mastorakos, G., Ilias, I., Mitsiades, N.: Apoptosis and the pathogenesis of Hashimoto’s thyroiditis, Epitheorese Klin. Farmakol. Farmakokinet. 14(1): 19-24 (2000) | |
| Publication Date | Received for publication: 6 December 1999
Accepted for publication: 10 December 1999 |
|
| Full Text Language | English | |
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)
pharmakonpress[at]pharmakonpress[.]gr |
|
| Keywords | Hashimoto’s thyroiditis, pathogenesis, apoptosis. | |
| Other Terms | review article | |
| Summary | The Fas protein, its ligand FasL and the Bcl-2 gene play major roles in apoptosis. Follicular cells in Hashimoto’s thyroiditis undergo apoptosis by concomitant upregulation of FasL and Fas and downregulation of Bcl-2 proteins. Autoimmune disorders with epithelial cell destruction, including Hashimoto’s thyroiditis, might share a common pathophysiology by which the target cells are engaged in a suicidal / fratricidal mode of death involving Fas /FasL interaction. Therapeutic interventions on genes involved in central cell death can be envisaged. | |
| References | 1. Thompson C.B.: Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-1462 (1995)
2. Nagata S., Golstein P.: The Fas death factor. Science 267: 1449-1456(1995) 3. Kong I., Ogawa N., Nakabayashi T.: Fas and FasL expression in the salivary glands of patients with primary Sjogren’s syndrome. Arthritis Rheum 40: 87-97 (1997) 4. Chervonsky A.V., Wang Y., Wong F.S., et al.: The role of Fas in autoimmune diabetes. Cell 89: 17-24 (1997) 5. Iwamoto M., Koji T., Makiyama K., Kobayashi N., Nakane P.K.: Apoptosis of crypt epithelial cells in ulcerative colitis. J. Pathol 186: 152-159 (1996) 6. Giordano C., Stassi G., De Maria R.t et al. : Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto’s thyroiditis. Science 275: 960-963 (1997) 7. Krajewski S., Bodrug S., Krajewska M., et al.: Immuno-histochemical analysis of McI-1 protein in human tissues. Differential regulation of Mcl-1 and Bc-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am. J. Pathol. 146: 1309-1319 (1995) 8. Pollina L, Pacini F., Fontanini G., Vignati S., Bevilacqua G., Basolo F.: Bcl-2, p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinoma. Br. J. Cancer 73: 139-143 (1996) 9. Berg J.P.: Autocrine/paracrine cell death in Hashimoto’s thyroiditis. Eur. J. Endocr. 137: 122-123 (1997) 10. Miotsiades N., Poulaki V., Kotoula V., Mastorakos G., Tselenis-Balafoutas S., Koutras D,, Tsokos M:. Fas/Fas ligand up-regulation and BCL-2 down-regulation may be significant in the pathogenesis of Hashimoto’s thyroiditis. J. Clin. Endocrinol. Metab. (1998) 11. Ju S.T., Panka D.J., Cui H., et al.: Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373: 444-448 (1995) 12. Kawakami A., Eguchi K.t Matsuoka N. et al.: Thyroid-stimulating hormone inhibits Fas antigen-mediated apoptosis of human thyrocytes in vitro. Endocrinology 137: 3163-3169(1996) |
|
| Relative Papers |
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
| ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2000 – ANNUAL SUBSCRIPTION 2000 | |
| Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά – English |
| Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)
pharmakonpress[at]pharmakonpress[.]gr |
| Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)
pharmakonpress[at]pharmakonpress[.]gr |
|